Last reviewed · How we verify
desvenlafaxine succinate sustained release
Desvenlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability.
Desvenlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.
At a glance
| Generic name | desvenlafaxine succinate sustained release |
|---|---|
| Also known as | DVS-233 SR, Pristiq, Pristiq |
| Sponsor | Pfizer |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Target | Serotonin transporter (SERT) and norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Desvenlafaxine is the active metabolite of venlafaxine and functions as a serotonin-norepinephrine reuptake inhibitor (SNRI). By blocking the reuptake transporters for both serotonin and norepinephrine, it increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their signaling and producing antidepressant and anxiolytic effects. The sustained-release formulation provides steady-state drug levels with once-daily dosing.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Social anxiety disorder
- Panic disorder
- Vasomotor symptoms associated with menopause
Common side effects
- Nausea
- Dizziness
- Headache
- Insomnia
- Somnolence
- Hypertension
- Sexual dysfunction
- Sweating
- Dry mouth
Key clinical trials
- Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder (NA)
- Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women (PHASE3)
- Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Study of Desvenlafaxine in Treating Major Depressive Disorder. (PHASE3)
- Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder (PHASE2)
- A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD (PHASE3)
- Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD) (PHASE3)
- A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- desvenlafaxine succinate sustained release CI brief — competitive landscape report
- desvenlafaxine succinate sustained release updates RSS · CI watch RSS
- Pfizer portfolio CI